Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNK-UT in Refractory Acute GVHD
NCT06750133Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CNK-UT001 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of Treatment Related adverse events at 1 year and Identification of Maximum Tolerated Dose & incidence of Dose-limiting Toxicities at 21 days. Started Dec 2024; status: recruiting.
02
Drugs
CNK-UT001
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06750133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750133.